Live Feed

8-A12B - SARATOGA INVESTMENT CORP. (0001377936) (Filer)

8-K - Columbus Circle Capital Corp II (0002088805) (Filer)

S-8 - Bit Digital, Inc (0001710350) (Filer)

Morgan Stanley downgraded Qfin Holdings from Overweight to Equal-Weight and set a new price target of $13.00

Sunnyvale, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (OTCQB:ASNS), a market leader in cyber-hardened, rapid deployment networking solutions for IoT, military, government, and broadband applications, participated recently in AFCEA TechNet Augusta, one of the premier U.S. defense and industry events focused on military cyber, network modernization, and "C5ISR" (Command, Control, Computers, Communications, Cyber, Intelligence, Surveillance, and Reconnaissance). The event brought together organizations and leaders from across the U.S. Army's communications, cyber, network operations communities, providing a firsthand look at the priorities driving military network moder

8-K - SARATOGA INVESTMENT CORP. (0001377936) (Filer)

CERT - Haleon plc (0001900304) (Filer)

Waystar AltitudeAI™ innovations autonomously execute work, connect intelligence to action, and realize significant outcomes for providersLEHI, Utah and LOUISVILLE, Ky., Aug. 26, 2026 /PRNewswire/ -- Waystar (NASDAQ:WAY), a provider of leading healthcare payment software, today unveiled new Waystar AltitudeAI-powered agentic capabilities that autonomously take action across critical revenue cycle workflows, advancing the company's vision for an autonomous revenue cycle. Built on Waystar's end-to-end platform, payer connectivity, and proprietary data spanning more than 7.5 billion transactions and approximately 60% of U.S. patients, these innovations advance Waystar'

JAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous dermatomyositis (DM), including measurements of disease activity, itch, and skin-related quality of lifeIn patients with at least moderate itch at baseline, clinically meaningful improvements were observed as early as Week 4 in 54% of brepocitinib 30 mg patients versus 10% with placebo, increasing to 74% versus 33%, respectively, by Week 52Nearly half of brepocitinib 30 mg treated patients with moderate-to-severe skin disease at baseline achieved remission-level outcomes by Week

Image 1 Michael Arbus, CEO of Moomoo Financial Canada and the winner of the Canada’s Top Trader competition, Dinghao Zhang at the Moomoo Store at CF Markville, located in Markham, Ontario, Canada.  TORONTO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Moomoo Financial Canada has announced the winner of its inaugural Canada's Top Trader Competition, the country's first live, real-money national trading competition held in partnership with Nasdaq. Running from June 1 to July 31, 2026, the competition attracted more than 8,000 registered participants from across the country and generated the highest trading activity in Moomoo Financial Canada’s history. Over two months, investors competed using thei

Guinness renews deal as the Official Beer of the Notre Dame Fighting Irish Alumni and Fans and re-signs Hall of Fame quarterback Joe MontanaNEW YORK, Aug. 26, 2026 /PRNewswire/ -- College football is back, and Guinness has plenty to raise a pint to! The brewing Irish and the Fighting Irish are teaming up once again as Guinness extends its partnership with Notre Dame Athletics for another three seasons, remaining the Official Beer of the Notre Dame Fighting Irish Alumni and Fans. Since first coming together in 2020, Guinness and Notre Dame have proven some partnerships are as natural as pints and football. Guinness is also re-si

N-PX - BlackRock 2037 Municipal Target Term Trust (0001832871) (Filer)

AI infrastructure silicon delivered from concept to tape-out in under six weeks Keysight Technologies, Inc. (NYSE:KEYS) today announced that AttoTude Inc., a pioneer of next-generation ASICs over Dielectric interconnect technology for AI and hyperscale data center applications, has expanded its use of Keysight EDA software to manage its full IC design workflow. As a result, AttoTude has reduced its design cycles by more than 50% while achieving first-pass silicon success across advanced RF, sub-THz, and THz tape-outs that underpin its guided-wave interconnect platform. Design velocity is emerging as a competitive advantage, with global semiconductor revenue forecast to exceed $1.3 trill

CAMARILLO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Salem Media, Inc. (OTCQX:SALM) today released new findings from BibleStudyTools.com, the largest free online Bible study resource and part of Salem Web Network. The data shows that young adults remain the most active generation reading Scripture online, countering a widely held assumption that they are disengaging from the Bible. Using first-party analytics from millions of readers, the Young Adults and the Bible study found that adults ages 25 to 34 are the single largest age group using BibleStudyTools.com, a position they have held for years. Nearly four in ten of the site's readers are under the age of 35. The data also revealed a

N-PX - BlackRock Municipal 2030 Target Term Trust (0001528437) (Filer)

N-PX - BlackRock Taxable Municipal Bond Trust (0001493683) (Filer)

N-PX - Cannae Holdings, Inc. (0001704720) (Filer)

N-PX - BLACKROCK CREDIT ALLOCATION INCOME TRUST (0001379384) (Filer)

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.Complete responses were observed in all but one organ system (only one participant had lower GI involvement).Favorable safe

N-PX - PIMCO CORPORATE & INCOME STRATEGY FUND (0001160990) (Filer)